FDA Approves Almirall’s Klisyri for the Treatment of AKs on Expanded Area of Face or Scalp Up to 100 cm2
The U.S. Food and Drug Administration (FDA) approved Almirall’s recent supplemental New Drug Application (sNDA) to expand the use area of tirbanibulin (Klisyri) for the treatment of actinic keratosis (AK) on the face or scalp up to 100 cm2. Klisyri, a microtubule inhibitor ointment, is now approved in a 350 mg package size and is […]